Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers by Williamson K M, Patterson J H, McQueen R H, Adams K F, Pieper J A in Clinical pharmacology and therapeutics (1998). PubMed

Abstract

Losartan is metabolized by CYP2C9 and CYP3A4 to an active metabolite, E3174, which has greater antihypertensive activity than the parent compound. Coadministered drugs that inhibit or induce metabolic processes may therefore alter the pharmacokinetics and pharmacologic response of losartan and E3174.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

None.